A dose-dependent reduction of phosphorylated KIT in tumor tissue was observed over time (Fig. 4A) which translated also into dose-dependent inhibition of downstream ERK1/2 phosphorylation (Supplementary Fig. S4A), in line with the cellular data. This evidence concerns the gene MAPK3 and neoplasm.